Literature DB >> 26951185

Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?

Clotilde Debove1, Nathalie Guedj2, Ecoline Tribillon1, Léon Maggiori1, Magaly Zappa3, Yves Panis4,5.   

Abstract

PURPOSE: The purpose of this study is to assess if local excision (LE) could be proposed if suspicion of complete tumor response (CR) after neoadjuvant chemoradiotherapy (CRT) for low rectal cancer (LRC) and this despite a potential risk of nodes (N+) or other tumor deposits (OTD) left in place. The aim was to assess in patients with LRC treated by CRT: (a) pathologic results of LE and total mesorectal excision (TME) in case of preoperative suspicion of CR and (b) the risk of N+ or OTD on TME if ypT0-Tis-T1 tumor. PATIENTS: Among 202 patients with LRC after CRT, 33 (16 %) with suspicion of CR underwent LE (n = 20) because of comorbidities and/or indication of definitive stoma or TME (n = 13). Pathologic examination of LE and TME specimens and oncological outcomes were assessed. Furthermore, 40/202 patients with pathologic CR on TME specimen (ypT0-Tis-T1) were assessed for possible N+ or OTD.
RESULTS: In the 33 patients with suspicion of CR: (a) after LE, tumor was ypT0-Tis-T1 in only 15/20 cases (75 %); (b) after TME, tumor was ypT0-Tis-T1 in only 7/13 cases (54 %). Among 40 patients with ypT0-Tis-T1 tumor on TME specimen, 4 (10 %) presented N+ and/or OTD.
CONCLUSION: In LRC with suspicion of CR after CRT, LE deserves a word of caution: 25 % of patients have in fact ypT2-T3 tumors. Furthermore, in patients with ypT0-Tis or T1 on TME specimen, a 10 % risk of N+ and/or ODT is observed. Thus, patient with suspicion of CR after CRT and treated by LE is exposed to a possible incomplete oncologic treatment.

Entities:  

Keywords:  Chemoradiotherapy; Complete tumor response; Local excision; Low rectal cancer

Mesh:

Year:  2016        PMID: 26951185     DOI: 10.1007/s00384-016-2546-1

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  35 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

Review 3.  Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  S T Martin; H M Heneghan; D C Winter
Journal:  Br J Surg       Date:  2012-02-23       Impact factor: 6.939

4.  Multicenter Evaluation of Rectal cancer ReImaging pOst Neoadjuvant (MERRION) Therapy.

Authors:  Ann M Hanly; Elizabeth M Ryan; Ailín C Rogers; Deborah A McNamara; Robert D Madoff; Desmond C Winter
Journal:  Ann Surg       Date:  2014-04       Impact factor: 12.969

5.  Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Salvatore Pucciarelli; Carlo Capirci; Urso Emanuele; Paola Toppan; Maria Luisa Friso; Gian Maria Pennelli; Giovanni Crepaldi; Lara Pasetto; Donato Nitti; Mario Lise
Journal:  Ann Surg Oncol       Date:  2005-02-04       Impact factor: 5.344

6.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

7.  A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy.

Authors:  G Lezoche; M Baldarelli; Mario Guerrieri; A M Paganini; A De Sanctis; S Bartolacci; E Lezoche
Journal:  Surg Endosc       Date:  2007-10-18       Impact factor: 4.584

8.  Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies.

Authors:  Fausto Petrelli; Giovanni Sgroi; Enrico Sarti; Sandro Barni
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

9.  Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.

Authors:  In Ja Park; Y Nancy You; John M Skibber; Miguel A Rodriguez-Bigas; Barry Feig; Sa Nguyen; Chung-Yuan Hu; George J Chang
Journal:  Dis Colon Rectum       Date:  2013-02       Impact factor: 4.585

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  3 in total

1.  Endoscopy-Based Deep Convolutional Neural Network Predicts Response to Neoadjuvant Treatment for Locally Advanced Rectal Cancer.

Authors:  Xijie Chen; Junguo Chen; Xiaosheng He; Liang Xu; Wei Liu; Dezheng Lin; Yuxuan Luo; Yue Feng; Lei Lian; Jiancong Hu; Ping Lan
Journal:  Front Physiol       Date:  2022-04-27       Impact factor: 4.755

2.  Preoperative chemoradiotherapy followed by local excision in clinical T2N0 rectal cancer.

Authors:  Young Seob Shin; Yong Sik Yoon; Seok-Byung Lim; Chang Sik Yu; Tae Won Kim; Heung Moon Chang; Jin-Hong Park; Seung Do Ahn; Sang-Wook Lee; Eun Kyung Choi; Jin Cheon Kim; Jong Hoon Kim
Journal:  Radiat Oncol J       Date:  2016-09-28

3.  Assessment of clinical and pathological complete response after neoadjuvant chemoradiotherapy in rectal adenocarcinoma and its therapeutic implications.

Authors:  Sorin Tiberiu Alexandrescu; Adrian Vasile Dumitru; Ruxandra Doina Babiuc; Radu Virgil Costea
Journal:  Rom J Morphol Embryol       Date:  2021 Apr-Jun       Impact factor: 1.033

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.